仁和药业开盘涨停，公司子公司与合作方联合研发全球首款ULook脑机交互智能眼镜。 ...

转自：智通财经 【仁和药业：子公司与合作方联合研发全球首款ULook脑机交互智能眼镜】智通财经8月19日电，仁和 药业在互动平台表示，公司的子公司（闪亮明眸公司）与合作方联合研发了全球首款ULook脑机交互智 能眼镜。该眼镜系脑机接口技术与眼健康领域的深度融合，实现了"脑眼协同"，是全球首台"戴在鼻梁 上的脑机"。该脑机智能眼镜集成EEG（脑电图）、红外测距等多项传感器，构建"眼-脑-心理"三维联动 机制，具有视力训练、提升专注力、用眼监测及情绪分析四大核心功能，综合解决青少年健康用眼问 题。 ...

天眼查商业履历信息显示，仁和药业股份有限公司，成立于1996年，位于宜春市，是一家以从事医药制 造业为主的企业。企业注册资本139993.8234万人民币，实缴资本139993.8234万人民币。公司法定代表 人为杨潇。 通过天眼查大数据分析，仁和药业股份有限公司共对外投资了38家企业，参与招投标项目2295次，知识 产权方面有商标信息63条，专利信息3条，此外企业还拥有行政许可6个。 来源：金融界 金融界消息 截至2025年8月8日收盘，仁和药业（000650）报收于5.78元，上涨0.17%，换手率1.65%， 成交量22.00万手，成交金额1.27亿元。 资金流向方面，今日主力资金净流出1262.01万元，占比成交额9.91%。其中，超大单净流出564.09万 元、占成交额4.43%，大单净流出697.91万元、占成交额5.48%，中单净流出流出463.52万元、占成交额 3.64%，小单净流入1725.53万元、占成交额13.55%。 仁和药业最新一期业绩显示，截至2025一季报，公司营业总收入9.86亿元、同比减少20.36%，归属净利 润1.64亿元，同比减少7.33%，扣非净利润1.02亿元，同 ...

Group 1: Epidemic Overview - The recent outbreak of Chikungunya fever in southern China has led to nearly 3,000 new cases reported in just one week, primarily in Guangdong province, affecting over ten cities [1][3] - The majority of cases are concentrated in Foshan, accounting for 95% of the total cases in Guangdong, with no severe cases or deaths reported so far [3] Group 2: Government Response and Guidelines - The National Health Commission has released the "Chikungunya Fever Diagnosis and Treatment Plan (2025 Edition)," emphasizing that the disease is preventable, controllable, and treatable [3][6] - The plan incorporates traditional Chinese medicine (TCM) approaches, highlighting the role of TCM in alleviating symptoms and promoting recovery [6] Group 3: Company Initiatives in Diagnostics and Treatment - Several listed companies in the IVD (in vitro diagnostics) sector are actively developing testing products and treatment solutions for Chikungunya fever [4][5] - Shenzhen BGI Technology Co., Ltd. has introduced the T1+ gene sequencer, which can provide comprehensive genomic analysis within 6-8 hours, aiding in rapid response to the outbreak [4] - Wanfu Biology has developed multiple Chikungunya virus detection products, creating a closed-loop system for monitoring and diagnosis [4] Group 4: Traditional Chinese Medicine Applications - TCM is being utilized for symptomatic treatment of Chikungunya fever, with specific formulations recommended for managing symptoms like fever and joint pain [6][7] - Companies such as Guangdong Yifang Pharmaceutical and Step Long Pharmaceutical are producing traditional Chinese medicines that may assist in treating Chikungunya fever [7]

证券日报网讯仁和药业（000650）8月5日在互动平台回答投资者提问时表示，公司长期以来，一直有安 宫牛黄丸生产和销售。公司生产的安宫牛黄丸，遵循古法精制，产品质量稳定可靠，目前在各大医院、 药店、诊所均有销售。 ...

Group 1 - The core viewpoint of the news is that Renhe Pharmaceutical (000650) has shown a slight increase in stock price, with a closing price of 5.94 yuan, up by 1.02% as of August 1, 2025 [1] - The company reported a total operating revenue of 986 million yuan for the first quarter of 2025, a year-on-year decrease of 20.36%, while the net profit attributable to shareholders was 164 million yuan, down by 7.33% [1] - The company's liquidity ratios are strong, with a current ratio of 8.246 and a quick ratio of 7.594, indicating good short-term financial health [1] Group 2 - Renhe Pharmaceutical has made investments in 38 companies and participated in 2,295 bidding projects, showcasing its active engagement in the market [2] - The company holds 63 trademark registrations and 3 patents, reflecting its focus on intellectual property [2] - Renhe Pharmaceutical has obtained 6 administrative licenses, indicating compliance with regulatory requirements [2]

近期举行的2025世界人工智能大会掀起了科技领域的狂欢，背后折射出的是新兴产业和产品的最新排 位。 在这场卡位战中，年初还以"百镜大战"之势席卷科技圈的智能眼镜却并未迎来井喷，迭代节奏和入局企 业数量都很克制，不少厂家还在观望用户反馈，期待小米、阿里这类玩家先行"教育"市场。消费方面， 刚需用户和科技爱好者还是主力军。今年6月，知名艺人刘宇宁就在出国拍摄时戴上了主打实时翻译的 智能眼镜。而为了激发用户的购买意愿，厂商也玩出了不少"花活"，如Meta联名奢侈品牌Prada，老凤 祥推出了适老化AI（人工智能）眼镜，仁和药业（000650）旗下品牌推出了脑机智能眼镜等。 近日，北京智源人工智能研究院研究员、北京大学访问学者赵仲夏接受了记者的采访。他认为，智能眼 镜是企业接入AI的重要端口，已经避无可避，其核心竞争要素是大模型能力，同时需要围绕超级应 用、AI入口等搭建完整的生态。玩家方面，赵仲夏认为未来三类公司有望争得先机：有大模型的公 司、有AI应用入口的公司和有硬件生态的公司。在市场完全培育好之前，智能眼镜无妨以首饰、潮玩 等形态出现，吸引更多用户入场。 更多厂商还在观望 目前市场上智能眼镜的技术路径主要有A ...

Core Viewpoint - Renhe Pharmaceutical (000650) has received the registration certificate for Entecavir tablets in 2021, which is an oral antiviral drug used for the treatment of hepatitis B infection [1] Company Summary - The company specializes in Entecavir, which selectively inhibits the hepatitis B virus [1] - Entecavir is primarily used for treating adults with active viral replication and persistently elevated serum transaminases, or with histologically active lesions in chronic hepatitis B [1]

Core Viewpoint - The company has received a drug registration certificate for Entecavir tablets in 2021, which is used for the treatment of hepatitis B infection [2]. Company Products - Entecavir is an oral antiviral medication that selectively inhibits the hepatitis B virus, primarily used for treating adults with active viral replication and elevated serum transaminases, or active disease in liver histology [2].

Group 1: Overview of Chikungunya Fever - Chikungunya virus is spreading globally, with 119 countries reporting cases and approximately 5.5 million people at risk of infection [1] - In Foshan, Guangdong Province, over 4,000 confirmed cases have been reported, primarily mild cases [1] Group 2: Symptoms and Treatment - Chikungunya fever is characterized by high fever and severe joint pain, particularly affecting small joints [2] - There is currently no specific treatment or widely used vaccine; management is primarily supportive, focusing on symptom relief [3] Group 3: Market Response and Company Involvement - Investors are inquiring about companies with products related to Chikungunya fever, focusing on mosquito repellent products, testing kits, and antipyretic and analgesic medications [4] - Companies like Rainbow Group, Runben Co., and Weigao Medical have reported an increase in sales of mosquito repellent products [5][6] - Pharmaceutical companies such as Renhe Pharmaceutical and Xinhua Pharmaceutical have indicated they offer products for fever and pain relief [7] Group 4: Testing Products - Companies like Kehua Bio, YHLO Biotech, and Shuoshi Bio have developed testing kits for Chikungunya virus [8] - YHLO Biotech has a rapid screening kit for Chikungunya, currently used for research purposes [8] - The market interest in these companies has led to notable stock price increases since the news of the outbreak [8]